Palatin Technologies (PTN) Cash & Equivalents (2010 - 2026)
Palatin Technologies' (PTN) quarterly Cash & Equivalents came in at $10.2 million in Q1 2026, up 303.14% YoY from $2.5 million in Q1 2025, and down 29.82% on a QoQ basis from $14.5 million in Q4 2025.
Palatin Technologies (PTN) Cash & Equivalents (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Cash & Equivalents data on file, last reported at $10.2 million in Q1 2026.
- Quarterly Cash & Equivalents rose 303.14% year-over-year to $10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.2 million (up 303.14% YoY) and the FY2025 annual result came in at $2.6 million, down 73.09% from the prior year.
- Cash & Equivalents eased to $10.2 million in Q1 2026, from $14.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $37.7 million in Q1 2022 to a low of $1.3 million in Q3 2025.
- A 5-year average of $12.3 million and a median of $9.5 million in 2024 frame the typical range for Cash & Equivalents.
- The widest YoY moves for Cash & Equivalents: up 323.7% in 2025, down 74.83% in 2025.
- Tracing PTN's Cash & Equivalents over 5 years: stood at $21.2 million in 2022, then tumbled by 55.22% to $9.5 million in 2023, then sank by 63.98% to $3.4 million in 2024, then soared by 323.7% to $14.5 million in 2025, then dropped by 29.82% to $10.2 million in 2026.
- The last three Cash & Equivalents figures came in at $10.2 million (Q1 2026), $14.5 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 10.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.16 Mn |
| Dec 31, 2025 | 14.48 Mn |
| Sep 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 2.56 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 3.42 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Jun 30, 2024 | 9.53 Mn |
| Mar 31, 2024 | 10.01 Mn |
| Dec 31, 2023 | 9.49 Mn |
| Sep 30, 2023 | 5.52 Mn |
| Jun 30, 2023 | 7.99 Mn |
| Mar 31, 2023 | 19.63 Mn |
| Dec 31, 2022 | 21.18 Mn |
| Sep 30, 2022 | 21.19 Mn |
| Jun 30, 2022 | 29.94 Mn |
| Mar 31, 2022 | 37.72 Mn |
| Dec 31, 2021 | 47.33 Mn |
| Sep 30, 2021 | 52.55 Mn |
| Jun 30, 2021 | 60.10 Mn |